NaV1.9 behaves very differently from other sodium channel isoforms, so working with a partner who understands those differences intricately is critical to drive your project forward.
We explore the channel’s unique fast and slow inactivation properties using Qube 384 and QPatch 48 platforms, helping to build more predictive screening assays for state-dependent inhibitors. Download the poster ‘Evaluation of hNav1.9 Screening Cascade for Analgesic Drug Discovery’.
This depth of biophysical understanding is what allows us to design assays that go beyond routine screening. Contact us to learn more.
 |  |
Development of a robust hNaV1.9 high-throughput screening assay on the Sophion Qube384 platform. This is complemented by a suite of ion channel selectivity assays and sensory neuron recordings to create a versatile screening cascade to support NaV1.9 drug discovery programmes.
Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.